TransMedics Group, Inc. (TMDX) Retained Earnings
The retained earnings for TransMedics Group, Inc. (TMDX) is $-277.95 Million with a year-over-year change of +40.64%. Retained earnings represent the cumulative net income that has been kept by the company rather than distributed to shareholders as dividends. It's a key component of shareholders' equity.
TMDX Retained Earnings Chart
Current Retained Earnings
$-277.95M
$-277.95 Million
Year-over-Year Change
+40.64%
vs. $-468.24M prior year
Historical Data
10
Years of data available
Annual Retained Earnings History
| Year | Retained Earnings | YoY Change | % Change |
|---|---|---|---|
| 2025 | $-277.95M | +$190.29M | +40.64% |
| 2024 | $-468.24M | +$35.46M | +7.04% |
| 2023 | $-503.70M | $-25.03M | -5.23% |
| 2022 | $-478.68M | $-36.23M | -8.19% |
| 2021 | $-442.45M | $-44.22M | -11.10% |
| 2020 | $-398.23M | $-28.75M | -7.78% |
| 2019 | $-369.48M | $-33.55M | -9.99% |
| 2018 | $-335.94M | $-23.76M | -7.61% |
| 2017 | $-312.18M | $-20.82M | -7.15% |
| 2016 | $-291.36M | — | — |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein